Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials ...

Tezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also decreasing need for ...

Secondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.

FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...

Full Year 2024 Results Key Financial Results Revenue: UK£31.4b (up 3.5% from FY 2023). Net ...

With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

GSK has joined a lengthening list of companies that have paused diversity, equity, and inclusion (DEI) targets under pressure ...

In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

Now biometric authentication in your home state is possible when you do GST registration in another state, GSTN Advisory on ...

GSK (GSK) announced the US Food and Drug Administration, FDA, has accepted for review the Biologics License Application, BLA, for the use of ...